

Gautham Gampa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12065987/publications.pdf>

Version: 2024-02-01

11
papers

288
citations

1040056

9
h-index

1372567

10
g-index

11
all docs

11
docs citations

11
times ranked

404
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>In Vivo</i> Efficacy of Tesevatinib in EGFR-Amplified Patient-Derived Xenograft Glioblastoma Models May Be Limited by Tissue Binding and Compensatory Signaling. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1009-1018.	4.1	11
2	Influence of transporters in treating cancers in the CNS. , 2020, , 277-301.		2
3	Enhancing Brain Retention of a KIF11 Inhibitor Significantly Improves its Efficacy in a Mouse Model of Glioblastoma. <i>Scientific Reports</i> , 2020, 10, 6524.	3.3	20
4	Brain Distributional Kinetics of a Novel MDM2 Inhibitor SAR405838: Implications for Use in Brain Tumor Therapy. <i>Drug Metabolism and Disposition</i> , 2019, 47, 1403-1414.	3.3	13
5	Drug Concentration Asymmetry in Tissues and Plasma for Small Molecule-Related Therapeutic Modalities. <i>Drug Metabolism and Disposition</i> , 2019, 47, 1122-1135.	3.3	79
6	Brain Distribution and Active Efflux of Three panRAF Inhibitors: Considerations in the Treatment of Melanoma Brain Metastases. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 368, 446-461.	2.5	15
7	E6201, an intravenous MEK1 inhibitor, achieves an exceptional response in BRAF V600E-mutated metastatic malignant melanoma with brain metastases. <i>Investigational New Drugs</i> , 2019, 37, 636-645.	2.6	22
8	Brain Distribution of a Novel MEK Inhibitor E6201: Implications in the Treatment of Melanoma Brain Metastases. <i>Drug Metabolism and Disposition</i> , 2018, 46, 658-666.	3.3	24
9	Barriers to Effective Drug Treatment for Brain Metastases: A Multifactorial Problem in the Delivery of Precision Medicine. <i>Pharmaceutical Research</i> , 2018, 35, 177.	3.5	53
10	Drug delivery to melanoma brain metastases: Can current challenges lead to new opportunities?. <i>Pharmacological Research</i> , 2017, 123, 10-25.	7.1	31
11	Challenges in the Delivery of Therapies to Melanoma Brain Metastases. <i>Current Pharmacology Reports</i> , 2016, 2, 309-325.	3.0	18